NAD+ injectable side effects reported to FDA
The relevant safety reference for NAD+ Pen reports severe chills, shaking, vomiting and fatigue after NAD+ injectable drugs; some reports required medical treatment. FDA describes these reactions as consistent with excessive endotoxin levels. That statement concerns the reported injectable-drug context, not a confirmed finding about this catalogue pen. FDA sterile-compounding communication.
Consistency with excessive endotoxin levels is how FDA characterizes the reports. It should not be rewritten as proof of contamination, a known event frequency or a demonstrated cause of harm from this supplier item. FDA sterile-compounding communication.
Food-grade ingredients and sterile compounding
FDA's communication identifies NAD+ as nicotinamide adenine dinucleotide. It warns that food-grade ingredients require appropriate processing before sterile compounding because microbial and endotoxin contamination can harm patients. FDA sterile-compounding communication.
The warning addresses whether material is suitable for a sterile-compounding setting. It does not establish the supplier pen's grade, processing, sterility or contents. A NAD+ name can identify a research topic without providing those product-specific findings. FDA sterile-compounding communication.
NAD+ pen and vial presentations
This pre-filled NAD+ Pen is listed as 500mg. The separately documented NAD+ vial has 500mg / 1000mg variants. These are presentation amounts, not concentrations, delivery measurements or clinical instructions.
The meaningful safety takeaway remains the specific FDA communication: reported injectable reactions and an ingredient-suitability warning. Neither the pen format nor a comparison of catalogue amounts resolves that safety question, and neither source supplies a human aging or wellness result for this product. FDA sterile-compounding communication.
